<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622477</url>
  </required_header>
  <id_info>
    <org_study_id>ML30016</org_study_id>
    <nct_id>NCT02622477</nct_id>
  </id_info>
  <brief_title>Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)</brief_title>
  <official_title>Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InterMune Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The purpose of the study was to assess the clinical outcome of patients with a mild to
      moderate IPF after a one-year therapy with Esbriet® (Pirfenidone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Categorical Decrease Of The Vital Capacity And Forced Volume Capacity (&gt;= 5 % Respectively 10% Compared To The Previous Examination Findings) Under Treatment</measure>
    <time_frame>-3 to 8 months before inclusion, appointment 0, and 3, 6, 9 and 12 months after appointment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Categorical Decrease of the 6-Minute Walking Distance (&gt;= 50 Metres Compared to the Previous Examination Findings) Under Treatment</measure>
    <time_frame>Appointment 0, and 3, 6, 9 and 12 months after appointment 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Appointment 0, and 3, 6, 9 and 12 months after appointment 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of the LCQ (Leicester Cough Questionnaire)</measure>
    <time_frame>Appointment 0, and 3, 6, 9 and 12 months after appointment 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of the SOBQ (Shortness of Breath Questionnaire)</measure>
    <time_frame>Appointment 0, and 3, 6, 9 and 12 months after appointment 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the Participants With Exacerbations</measure>
    <time_frame>Appointment 0, and 3, 6, 9 and 12 months after appointment 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cases Of Death (All, Idiopathic Pulmonary Fibrosis Associated)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the Participants, who After the 3 Week Titration Phase Receive the Full Maintenance Dosage Of Pirfenidone</measure>
    <time_frame>3, 6, 9 and 12 months after appointment 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Pirfenidone</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the Participants who Change the Dosage Of Pirfenidone</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for the Dosage Change</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for the Beginning, Change or Discontinuation of a Treatment of Comorbidities of Pirfenidone Associated Adverse Drug Reactions</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least one Adverse Drug Reaction Under the Therapy With Pirfenidone</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Participants with idiopathic pulmonary fibrosis</arm_group_label>
    <description>Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.</description>
    <arm_group_label>Participants with idiopathic pulmonary fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF), who
        had previously not yet been treated with Pirfenidone
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients with confident diagnosis of mild to moderate IPF, who had previously not yet
        been treated with Pirfenidone

        Exclusion Criteria:

        Hypersensitivity to the active substance or one of the other excipients of Pirfenidone
        Concomitant use of Fluvoxamin Severe hepatic impairment or end stage liver disease Severe
        renal impairment (Creatinine-Clearance &lt;30 ml/min) or end stage renal disease requiring
        dialysis Simultaneous participation in interventional studies Previously treated with
        Pirfenidone for longer than 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. med. Mathias Rolke und Dr. med. Peter Rückert</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evang. Lungenklinik Berlin Klinik für Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. med. Martin Hoster, Dr. Hans-G. Lange von Stocmeier, Michael Behn und w.</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Wilhelm Ammenwerth</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Coswig GmbH</name>
      <address>
        <city>Coswig</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Werra-Meißner GmbH</name>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Abteilung Pneumologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG; Universitätsmedizin Marburg, Campus Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Göttingen-Weende E.V.</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg Klinik für Kardiologie Angiologie u.Pneumologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Matthias Waltert</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxzentrum, Abt. Pneumologie</name>
      <address>
        <city>Münnerstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum üBAG</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>February 26, 2017</last_update_submitted>
  <last_update_submitted_qc>February 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

